PhotosVideosAllPeople
Line chart titled "Tepezza and Enspryng quarterly sales", worldwide sales per quarter in euros from Q1 2024 to Q2 2026, axis marked 0 to 600 million euros. The violet Tepezza line, Amgen's thyroid eye disease drug, moves between about €362m and €495m a quarter, from €390m to €495m. The light blue Enspryng line, Roche's, sits far below it and climbs slowly from €69m to €108m, about a fifth of Tepezza in the last quarter.